Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers

by Andriy Krendyukov, Sanjay Singhvi, Markus Zabransky
Published 2021-03-01

Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope for the treatment of adult patients with growth hormo...

by Paolo Beck-Peccoz, Francesco Minuto, Alfonso Leal-Cerro, Markus Zabransky, Günter Stalla
Published 2012-06-01

No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an obse...

by Paolo Beck-Peccoz, Charlotte Höybye, Robert D. Murray, Suat Simsek, Markus Zabransky, Hichem Zouater, Günter Stalla
Published 2019-12-01

Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope): data from the PATRO Adults study

by Paolo Beck-Peccoz, Charlotte Höybye, Robert D Murray, Suat Simsek, Markus Zabransky, Hichem Zouater, Günter Stalla
Published 2020-09-01

Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope in children requiring growth hormone treatm...

by Roland Pfäffle, Karl Otfried Schwab, Otilia Marginean, Mieczyslaw Walczak, Mieczyslaw Szalecki, Ellen Schuck, Markus Zabransky, Stefano Zucchini
Published 2013-02-01